Medicare Part D

Created in the Medicare Modernization Act (MMA) of 2003, and formally implemented in 2006, Medicare Part D provides affordable access to outpatient prescription drug coverage for seniors and people with disabilities.

The Prescription Drug User Fee Act (PDUFA) VI

History of PDUFA

Before the Prescription Drug User Fee Act (PDUFA), it often took the Food and Drug Administration (FDA) more than two years to review new medicines, and more than 70 percent of medicines were first approved outside of the United States.

The Biopharmaceutical Pipeline: Evolving Science, Hope for Patients

Rx Minute: Statins Value to Society & Risk Factors Linked to Alzheimer's

A recent article published in Health Affairs highlights the remarkable impact of cholesterol-lowering drugs known as statins on the treatment of cardiovascular disease in the U.S.

Debunking the Myths of Treating Hepatitis C

11.04.14 | By

A national dialogue is needed around the value of new medicines and cures and the role they play in improving patient health and helping to manage long-term spending in the U.S. health care system. Unfortunately, the debate around hepatitis C has, for the most part, been twisted to the point that modern-day cures are seen as a nuisance rather than a monumental step forward in the battle against disease. (This post was updated on August 5, 2014.)

Access to Combination Therapies in Exchanges (2014)

Combination therapies are medications that contain two or more pharmaceutical ingredients in a single dosage form (e.g., tablet, capsule) for the treatment of a condition. Oftentimes, patients living with chronic conditions—such as HIV and diabetes—rely on combination therapies because they reduce the number of medications or dosages a patient must take, which can increase adherence and clinical efficacy.

Strengthening the U.S.-Canada Relationship Through Innovative Partnerships

09.18.14 | By

Usually, when U.S. Secretary of Commerce Penny Pritzker holds a meeting with her Canadian counterpart, she meets with Minister of International Trade Edward Fast due to their overlapping issue areas. However, this week Secretary Pritzker will host a rare meeting with Canada’s Minister of Industry James Moore.

New Reports Demonstrate the Importance of Biopharmaceutical Industry Exports to U.S. Economy

09.05.14 | By

Earlier this week, the U.S. Department of Commerce released two new reports detailing the extraordinary impact that exports have on our economy. The new data revealed that exports supported more than 11 million jobs within the U.S.

Driving Amazing R&D Progress

09.02.14 | By

We are on the cusp of amazing progress in U.S. biopharmaceutical research and development, but without policies that help attract and retain research-based companies and partnerships to help bring new medicines to patients, we run the risk of losing our country’s competitive advantage.

One Stop for Innovation: PhRMA’s New

08.26.14 | By

It’s likely many of us have paused to think about what life would have been like in a bygone time and felt thankful for the modern comforts we enjoy, from refrigeration to cell phones. When looking at the progress we’ve made and the comforts we enjoy, medical innovation should be at the top of the list. Over the past 100 years, life expectancy has surpassed 80 years, devastating diseases have been eradicated and quality of life has dramatically improved.


Subscribe to RSS - Opinion